Dr Cho on Niraparib Rechallenge Plus Bevacizumab in Platinum-Sensitive, Recurrent Ovarian Cancer

"As of the data cutoff, the median follow-up period was 11.8 months, and the primary end point of the estimated 6-month PFS rate was 68%. The median PFS was 11.5 months."

Hyun-Woong Cho, MD, PhD, Department of Obstetrics and Gynecology, Korea University College of Medicine, discusses findings from the phase 2 KGOG 3056/NIRVANA-R trial (NCT04734665) evaluating niraparib (Zejula) rechallenge plus bevacizumab (Avastin) as maintenance therapy in patients with ​platinum-sensitive, recurrent ovarian cancer who were previously treated with a PARP inhibitor.

NIRVANA-R enrolled patients with recurrent, nonmucinous ovarian cancer who had previously received a PARP inhibitor, had received their penultimate line of chemotherapy at least 12 months prior to enrollment, and had achieved a complete response (CR) or partial response to platinum-based chemotherapy with or without bevacizumab. Enrolled patients (n = 44) received niraparib at an individualized starting dose in combination with bevacizumab at 15 mg every 3 weeks. The primary end point was 6-month progression-free survival (PFS) rate.

At a data cutoff of ​June 1, 2024, and a median follow-up of 11.8 months, the 6- and 12-month PFS rates were 68% (95% CI, 55%-85%) and 46% (95% CI, 31%-68%), respectively. The median PFS was 11.5 months (95% CI, 7.9-not reached).

Findings from a subgroup analysis revealed that the 6-month PFS outcomes with the combination favored patients with a long treatment-free interval following their most recent prior line of chemotherapy, as well as those who achieved a CR with their most recent platinum-based chemotherapy, Cho notes. Among patients with treatment-free intervals with their penultimate line of platinum-based chemotherapy lasting less than 24 months and at least 24 months, the 6-month PFS rates were 56% and 82%, respectively. 

Disclosures: Cho reported receiving honoraria/expenses for consulting/advisory board participation from Chong Kun Dang, GSK, Merck, MSD, Onconic Therapeutics, Roche, and Takeda; research funding from Boryung, Chong Kun Dang, and Hanmi; and participating in clinical trials or contracted research with AbbVie, Corcept, DualityBio, GSK, Merck, Onconic Therapeutics, Regeneron, and Sutro Biopharma.